Your Patients Can't Find Fluticasone. Here's How You Can Help.

As a prescriber, you've likely fielded calls from patients unable to fill their Fluticasone prescriptions. Since the discontinuation of Flovent in January 2024, the inhaled Fluticasone landscape has been marked by insurance disruptions, pharmacy stocking gaps, and patient confusion. These aren't problems that resolve themselves at the pharmacy counter—they often require prescriber intervention.

This guide provides a practical, step-by-step approach to helping your patients access Fluticasone or an appropriate alternative. For the broader clinical and policy context, see our provider briefing on the Fluticasone shortage.

Current Fluticasone Availability

As of early 2026, the availability picture for Fluticasone is as follows:

• Generic Fluticasone Propionate HFA inhaler: Available nationally from Prasco/Teva and other generic manufacturers. Not on the FDA drug shortage list. However, insurance coverage and pharmacy stocking remain inconsistent.
• Arnuity Ellipta (Fluticasone Furoate): Stable supply. Preferred by several commercial plans. Eligible for GSK's $35/month copay cap.
• OTC Fluticasone nasal spray: Widely available at retail. No access issues.
• Combination products (Advair generics, Breo Ellipta): Generally available, though pricing varies significantly.

Why Patients Can't Find Fluticasone

Understanding the root causes helps you intervene more effectively:

1. Insurance won't cover it. The authorized generic Fluticasone HFA is not on every formulary. Some plans require prior authorization or step therapy through QVAR or Arnuity first.
2. Pharmacy doesn't stock it. If a pharmacy's patient base has shifted to alternative ICS products, they may not maintain Fluticasone HFA inventory.
3. Cost is prohibitive. Without insurance, generic Fluticasone HFA costs $160-$310. This is a significant barrier for uninsured and underinsured patients.
4. Patients don't know the new product name. Some patients still ask for "Flovent" and are told it doesn't exist, not realizing the generic equivalent is available under a different name.

What Providers Can Do: 5 Steps

Step 1: Verify Insurance Coverage Before Prescribing

Before writing or renewing a Fluticasone prescription, check the patient's formulary if accessible through your EHR or pharmacy benefit tool. If Fluticasone Propionate HFA is non-formulary, consider prescribing the patient's plan's preferred ICS:

• Arnuity Ellipta (Fluticasone Furoate) — often preferred, GSK $35 copay cap eligible
• QVAR RediHaler (Beclomethasone) — common step-therapy first-line
• Asmanex (Mometasone) — once-daily option on some formularies
• Pulmicort (Budesonide) — especially useful for pediatric patients needing nebulization

Step 2: E-Prescribe to a Pharmacy with Confirmed Stock

When patients report that their pharmacy is out of Fluticasone, use Medfinder for Providers to identify nearby pharmacies with confirmed availability. E-prescribe directly to the pharmacy with stock to avoid transfer delays.

This is faster than asking patients to call around themselves, and it reduces the risk of patients going without their controller medication during the search.

Step 3: Submit Prior Authorizations Proactively

If the patient's plan requires prior authorization for Fluticasone, submit it proactively at the time of prescribing rather than waiting for a pharmacy rejection. Include:

• Specific diagnosis (asthma, COPD, etc.) with severity classification
• Documentation of prior ICS trials if step therapy is required
• Clinical rationale for Fluticasone specifically (e.g., prior good response, device preference, failed alternatives)
• Any contraindications to the plan's preferred alternatives

Step 4: Educate Patients on the Flovent-to-Generic Transition

Many patients are confused by the change. Take 30 seconds to explain:

• Flovent was discontinued, but the same medication is available as a generic
• The generic is called "Fluticasone Propionate HFA" — same drug, different label
• Insurance coverage may have changed; they should ask their pharmacist about coverage
• OTC nasal spray (Flonase) is a different product for a different condition

Consider printing or sharing the patient-facing article: Fluticasone shortage update for patients.

Step 5: Connect Patients with Cost-Saving Resources

For patients facing cost barriers:

• GSK Patient Assistance Program (gskforyou.com) — free medications for eligible uninsured patients
• Discount cards — GoodRx, SingleCare, RxSaver can reduce generic Fluticasone HFA to ~$160
• GSK $35 copay cap — applies to Arnuity Ellipta and Breo Ellipta for commercially insured patients
• NeedyMeds and RxAssist — directories of patient assistance programs

For a comprehensive cost resource to share with patients, see: How to save money on Fluticasone. For a provider-specific guide to cost navigation, see: How to help patients save money on Fluticasone.

Alternatives to Consider

When Fluticasone is unavailable or not covered, the following ICS products are clinically appropriate alternatives for most patients:

• Budesonide (Pulmicort Flexhaler, Pulmicort Respules): Well-established efficacy. Respules option for pediatric nebulization. Generic widely available.
• Mometasone (Asmanex Twisthaler/HFA): Once-daily dosing option. Similar efficacy profile to Fluticasone.
• Beclomethasone (QVAR RediHaler): Breath-actuated device. Ultrafine particle formulation for small airway delivery. Common formulary-preferred ICS.
• Ciclesonide (Alvesco): Prodrug with lower local side effect profile. Good option for patients with ICS-related oral candidiasis or dysphonia.

For patient-facing information on alternatives, share: Alternatives to Fluticasone.

Workflow Tips for Your Practice

• Flag high-risk patients. Identify patients currently on Fluticasone products in your EHR and proactively verify their coverage and supply status at annual visits or medication reconciliation touchpoints.
• Bookmark Medfinder for Providers. Add it to your workflow for when patients report pharmacy stock issues. A quick search can save the patient hours of phone calls.
• Prepare alternative prescriptions. Have a second-line ICS prescription ready to send if the patient's pharmacy can't fill Fluticasone. This avoids delays when the rejection comes back.
• Collaborate with your pharmacy team. If you work in a health system, coordinate with pharmacy to monitor ICS supply and proactively switch patients when necessary.
• Document everything. Note the specific product, dose, and insurance status in the chart. This makes future prior authorizations and appeals faster.

Final Thoughts

The post-Flovent landscape requires more prescriber engagement than a straightforward ICS prescription used to. But with the right tools and proactive approach, you can keep your patients on appropriate controller therapy without unnecessary gaps.

Medfinder for Providers is designed to help you navigate exactly this type of situation—real-time availability data, alternative identification, and patient resources all in one place.

For the full clinical context, refer to our Fluticasone shortage briefing for providers.